Article Details
Retrieved on: 2025-05-21 16:06:04
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Connect Biopharma's development of Rademikibart, a potential treatment for respiratory diseases like asthma and COPD, focusing on its rapid action and safety profile compared to existing therapies like Dupilumab. Tags reflect a focus on biopharma innovation in treating inflammatory and respiratory diseases in the U.S. under FDA consideration.
Article found on: www.citybiz.co
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here